These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21036697)

  • 1. Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response.
    Loriot Y; Mordant P; Brown BD; Bourhis J; Soria JC; Deutsch E
    Anticancer Res; 2010 Oct; 30(10):3869-78. PubMed ID: 21036697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.
    Hu Y; Bebb G; Tan S; Ng R; Yan H; Sartor JR; Mayer LD; Bally MB
    Clin Cancer Res; 2004 Nov; 10(22):7662-70. PubMed ID: 15569999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer.
    Yip KW; Mocanu JD; Au PY; Sleep GT; Huang D; Busson P; Yeh WC; Gilbert R; O'Sullivan B; Gullane P; Bastianutto C; Liu FF
    Clin Cancer Res; 2005 Nov; 11(22):8131-44. PubMed ID: 16299246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R; Carbone R; Reiss M; Lacy J
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer.
    Herbst RS; Frankel SR
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4245s-4248s. PubMed ID: 15217967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence.
    Ziegler A; Luedke GH; Fabbro D; Altmann KH; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 1997 Jul; 89(14):1027-36. PubMed ID: 9230884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
    Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
    Tortora G; Caputo R; Damiano V; Bianco R; Fontanini G; Cuccato S; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2001 Aug; 7(8):2537-44. PubMed ID: 11489837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irradiation of human prostate cancer cells increases uptake of antisense oligodeoxynucleotide.
    Anai S; Brown BD; Nakamura K; Goodison S; Hirao Y; Rosser CJ
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1161-8. PubMed ID: 17637391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
    Rudin CM; Kozloff M; Hoffman PC; Edelman MJ; Karnauskas R; Tomek R; Szeto L; Vokes EE
    J Clin Oncol; 2004 Mar; 22(6):1110-7. PubMed ID: 15020613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis, Bcl-2 antisense, and cancer therapy.
    Piro LD
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
    Benimetskaya L; Ayyanar K; Kornblum N; Castanotto D; Rossi J; Wu S; Lai J; Brown BD; Popova N; Miller P; McMicken H; Chen Y; Stein CA
    Clin Cancer Res; 2006 Aug; 12(16):4940-8. PubMed ID: 16914583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells.
    Zangemeister-Wittke U; Leech SH; Olie RA; Simões-Wüst AP; Gautschi O; Luedke GH; Natt F; Häner R; Martin P; Hall J; Nalin CM; Stahel RA
    Clin Cancer Res; 2000 Jun; 6(6):2547-55. PubMed ID: 10873111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G3139 induces cell death by caspase-dependent and -independent apoptosis on human melanoma cell lines.
    Nakamura S; Inui M; Kamei T; Nakase M; Okumura K; Tagawa T
    Oncol Rep; 2006 Jun; 15(6):1563-8. PubMed ID: 16685396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antitumor effect of chemotherapy and antisense-mediated ablation of the cell cycle inhibitor p27KIP-1.
    Achenbach TV; Müller R; Slater EP
    Clin Cancer Res; 2000 Aug; 6(8):3006-14. PubMed ID: 10955778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor regression by combination antisense therapy against Plk1 and Bcl-2.
    Elez R; Piiper A; Kronenberger B; Kock M; Brendel M; Hermann E; Pliquett U; Neumann E; Zeuzem S
    Oncogene; 2003 Jan; 22(1):69-80. PubMed ID: 12527909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
    Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer.
    Leonetti C; Biroccio A; D'Angelo C; Semple SC; Scarsella M; Zupi G
    Prostate; 2007 Sep; 67(13):1475-85. PubMed ID: 17654511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of ZGDHu-1 on proliferation and apoptosis of A549 cells in vitro and antitumor activity in vivo].
    Zhou YL; Hu WX; Lü YP; Qiu LN; Wang WS; Yang ZY; Liu JD; Rao GW
    Yao Xue Xue Bao; 2007 Jan; 42(1):26-34. PubMed ID: 17520803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.